<DOC>
	<DOCNO>NCT00131963</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , cyclophosphamide , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well doxorubicin , cyclophosphamide , and/or paclitaxel work treat woman nonmetastatic breast cancer .</brief_summary>
	<brief_title>A Pharmacogenomics Study Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin ( A ) /Cyclophosphamide © ) and/or Weekly Paclitaxel</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacogenomics adjuvant chemotherapy comprise doxorubicin cyclophosphamide and/or paclitaxel woman nonmetastatic invasive breast cancer . - Determine treatment-induced myelosuppression ( e.g. , neutropenia ) patient treat adjuvant doxorubicin cyclophosphamide polymorphisms drug activation metabolism gene . - Correlate incidence peripheral neuropathy pharmacogenomic analysis patient treat paclitaxel . Secondary - Determine response ( i.e. , relapse adjuvant set ) 10-year follow-up period patient treat regimen . OUTLINE : This multicenter study . Patients receive treatment The Cancer Leukemia Group B study ( CALGB ) CALGB-40101 OR assign receive 1 2 treatment regimen study . - Regimen 1 : Patients receive doxorubicin IV 10 minute cyclophosphamide IV 30 minute day 1 . Treatment repeat every 21 day 4 course . - Regimen 2 : Patients receive doxorubicin cyclophosphamide regimen 1 . Patients receive paclitaxel IV 1 hour weekly 12 week . After completion study treatment , patient follow 3 , 6 , 12 month annually 10 year . PROJECTED ACCRUAL : A total 500 patient ( 300 treat doxorubicin cyclophosphamide 200 treat paclitaxel ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Eligibility Criteria Histologically confirm invasive breast cancer node negative stage &gt; T1c T1b poor prognostic feature ( high grade , Her2/neu FISH positive , ER negative ) stage 2 ( T2 , N0 ) enrol CALGB 40101 , CALGB 49909 , National Cancer Institute Canada study MA21 node positive patient locally advance undergoing neoadjuvant chemotherapy either AC paclitaxel Age great equal 18 year . &gt; /=2 week major surgery ( wide excision / lumpectomy / mastectomy ) No evidence systemic metastasis Undergoing adjuvant treatment standard dose AC AC follow weekly Paclitaxel 80mg/m2 Adequate bone marrow , hepatic renal function ( absolute neutrophil count &gt; 1,500/ μl , platelet count &gt; 100,000/ μl , serum creatinine &lt; 2.0 mg/dl , total Bilirubin &lt; 2.0 x upper limit normal ( ULN ) Ability answer understand study surveillance questionnaires No concurrent drug therapy ( within 2 week ) agent know inducer inhibitor Cytochrome P450 ( CYP450 ) . Exclusion Criteria Other anticancer cytotoxic endocrine therapy , immunotherapy , biologic response modifier , Study Drugs concomitant medication know cause myelosuppression especially neutropenia neuropathy Eastern Cooperative Oncology Group Performance Status ( ECOG ) functional status &gt; 2 . Serious comorbidities include poorly control diabetes mellitus , ischaemic heart disease , uncontrolled hypertension active infection . Pregnancy Use growth factor cycle 1 chemotherapy ( AC ) pharmacokinetic evaluation Grade &gt; /=2 peripheral neuropathy symptom base National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Scale . Exception : chronic neurologic disorder review case case basis study PI . Prior treatment weekly paclitaxelDISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer , meet 1 follow criterion : Node negative disease AND meet 1 follow stage criterion : Primary tumor &gt; T1c Primary tumor &gt; T1b AND poor prognostic feature , define follow : Highgrade disease Human Epidermal Growth Factor Receptor 2 ( HER2 ) /neupositive disease fluorescence situ hybridization Estrogen receptornegative disease Stage II disease ( T2 , N0 ) Node positive nonmetastatic disease Locally advance disease AND receive neoadjuvant chemotherapy comprise doxorubicin cyclophosphamide OR paclitaxel Enrolled clinical trial CALGB40101 No evidence systemic metastasis Hormone receptor status : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage One A ( IA ) breast cancer</keyword>
	<keyword>stage Two ( II ) breast cancer</keyword>
	<keyword>stage Three A ( IIIA ) breast cancer</keyword>
	<keyword>stage Three B ( IIIB ) breast cancer</keyword>
	<keyword>stage Three C ( IIIC ) breast cancer</keyword>
	<keyword>stage One B ( IB ) breast cancer</keyword>
</DOC>